
Novel obesity drug could be ‘combination partner of choice’
Biotechnology company Antag Therapeutics has revealed promising results from its novel GIPR antagonist for the treatment of obesity. AT7687, a first-in-class GIPR antagonist, was trialled in a Phase I randomised, double-blind, placebo-controlled study. Results show AT7687 demonstrated a favourable safety and tolerability profile across all doses. The… Read More


